Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
复制标题
DOI：
10.1016/j.ajg.2012.03.006
复制
发表时间：
2012-03-01
期刊：
影响因子：
--
通讯作者：
Omar Khalifa, Mohamed
中科院分区：
文献类型：
--
作者：
Fawzy Montaser, Mohamed;Amin Sakr, Mohamed;Omar Khalifa, Mohamed
背景和研究目的：甲胎蛋白（AFP）并不是在所有的肝细胞癌（HCC）病例中分泌的，在多达40%的早期HCC患者中可能是正常的。α-l-岩藻糖苷酶（AFU）是一种存在于所有哺乳动物细胞中的溶酶体酶，已被提议作为肿瘤标志物，因为许多研究报告肝硬化和HCC患者中AFU血清水平升高。本研究的目的是评估AFU作为肝癌的肿瘤标志物的诊断价值和其预后作用，在后续intervention.Patients和方法：这项前瞻性病例对照研究进行了80例（40例肝癌患者和40例慢性肝病（CLD）作为患病对照），除了40名明显健康的个人谁作为健康对照组。结果：治疗组血清AFU水平较对照组明显升高（P
BACKGROUND AND STUDY AIMS: Alphafoetoprotein (AFP) is not secreted in all cases of hepatocellular carcinoma (HCC) and may be normal in as many as 40% of patients with early HCC. Alpha-l-fucosidase (AFU), a lysosomal enzyme present in all mammalian cells, has been proposed as a tumour marker since many studies reported increased AFU serum levels in patients with cirrhosis and HCC. This study aimed at evaluation of the diagnostic value of AFU as a tumour marker of HCC and its prognostic role in follow-up after intervention.PATIENTS AND METHODS: This prospective case-control study was conducted on 80 patients (40 patients with HCC and 40 patients with chronic liver disease (CLD) as diseased controls) in addition to 40 apparently healthy individuals who served as a healthy control group. AFU serum levels in the three groups were measured and compared.RESULTS: There was a statistically highly significant elevation (p